Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Imaging Studies VI: Voiding Cystourethrography and Cystography01:22

Imaging Studies VI: Voiding Cystourethrography and Cystography

Voiding Cystourethrography (VCUG) and Cystography are specialized radiographic procedures used to examine the structure and function of the bladder and urethra.Voiding Cystourethrography (VCUG)A Voiding Cystourethrogram (VCUG) is a diagnostic imaging procedure that assesses the anatomy and function of the lower urinary tract. It focuses on the bladder, bladder neck, and urethra, helping detect abnormalities such as vesicoureteral reflux (VUR)—the backward or reverse flow of urine into the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Single-event fast neutron time-of-flight spectrometry with a petawatt-laser-driven neutron source.

Nature communications·2026
Same author

Haematotoxicity of Craniospinal Radiochemotherapy for Metastatic Paediatric High-Grade Glioma.

Clinical oncology (Royal College of Radiologists (Great Britain))·2025
Same author

ESMO-ESTRO consensus statements on the safety of combining radiotherapy with immune checkpoint inhibitors, VEGF(R) inhibitors, or multitargeted tyrosine kinase inhibitors.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

[Less is more: dose de-escalation in early anal cancer-Clinical and functional aspects of quality of life from the PLATO-ACT4 trial].

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·2025
Same author

Reply to the Letter to the Editor by Perez et al. regarding "Survival among patients treated with total mesorectal excision or selective watch-and-wait after total neoadjuvant therapy: a pooled analysis of the CAO/ARO/AIO-12 and OPRA randomized phase II trials".

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Chemotherapy before or after preoperative chemoradiotherapy and surgery for locally advanced rectal cancer: 5-year results of the CAO/ARO/AIO-12 trial - a general pairwise comparison.

ESMO open·2025
Same journal

Exploring the Need for Plan Adaptation in Robustly Optimised Head and Neck Intensity Modulated Proton Therapy: A Dosimetric Perspective From Initial Institutional Experience.

Clinical oncology (Royal College of Radiologists (Great Britain))·2026
Same journal

Lifting the Lid on Best Practice in a Case of Oligometastatic Breast Cancer.

Clinical oncology (Royal College of Radiologists (Great Britain))·2026
Same journal

Standardisation of Imaging Surveillance for Patients With Metastatic Melanoma Stopping Immune Checkpoint Inhibitors.

Clinical oncology (Royal College of Radiologists (Great Britain))·2026
Same journal

Valuing Public Sector Data Assets: Methodological Perspectives From the Add-Aspirin Trial's Use of Healthcare Systems Data for Clinical Follow-Up.

Clinical oncology (Royal College of Radiologists (Great Britain))·2026
Same journal

Autologous Cell Therapy in Oncology: Current Landscape and Future Directions.

Clinical oncology (Royal College of Radiologists (Great Britain))·2026
Same journal

Proton Beam Therapy for Intracranial Germ Cell Tumors in Pediatric, Adolescent, and Young Adult Patients: A Single-Center Experience.

Clinical oncology (Royal College of Radiologists (Great Britain))·2026
See all related articles

Related Experiment Video

Updated: Jun 22, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

Radiochemotherapy for bladder cancer.

O J Ott1, C Rödel, C Weiss

  • 1Department of Radiation Oncology, University Hospitals Erlangen, Universitätsstrasse 27, Erlangen, Germany. oliver.ott@uk-erlangen.de

Clinical Oncology (Royal College of Radiologists (Great Britain))
|July 1, 2009
PubMed
Summary
This summary is machine-generated.

Multimodality treatment offers bladder preservation for muscle-invasive bladder cancer, achieving survival rates comparable to cystectomy. Careful patient selection and complete tumor resection are key for successful organ preservation.

More Related Videos

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment
08:43

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment

Published on: July 28, 2012

Related Experiment Videos

Last Updated: Jun 22, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment
08:43

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment

Published on: July 28, 2012

Area of Science:

  • Oncology
  • Urology

Background:

  • Standard treatment for muscle-invasive bladder cancer (MIBC) is cystectomy.
  • Multimodality treatment (MMT) offers an alternative, potentially preserving the bladder.

Purpose of the Study:

  • To evaluate the efficacy of MMT for MIBC organ preservation.
  • To identify prognostic factors for bladder preservation and overall survival.

Main Methods:

  • Analysis of prospective series including over 1000 patients treated with MMT.
  • Inclusion criteria: transurethral resection, radiation therapy, chemotherapy, and deep regional hyperthermia.
  • Multivariate analysis to determine prognostic factors.

Main Results:

  • Five-year overall survival rates of 50-60% reported with MMT.
  • Approximately 75% of survivors maintained their bladders.
  • Complete transurethral resection of bladder tumor (TURBT) identified as a strong prognostic factor for survival.

Conclusions:

  • MMT provides comparable survival to cystectomy for MIBC, with a high rate of bladder preservation.
  • Patient selection criteria (tumor size, stage, complete TURBT, no obstruction/metastasis) are crucial.
  • Future research should focus on optimizing radiation, chemotherapy, and molecular markers for patient selection.